BeyondSpring Inc.
Close on Oct 19, 2026
- Market cap
- $21.09M
- P/E (TTM)
- –
- Dividend yield
- –
About BeyondSpring
Pharmaceutical Preparations, SIC 2834
BeyondSpring is a clinical-stage biopharmaceutical enterprise specializing in the research and advancement of novel cancer treatments for patients confronting serious unmet therapeutic needs. Its premier candidate, Plinabulin, operates as a selective immunomodulating microtubule-binding drug engineered to stimulate immune defenses and counter acquired resistance associated with immune checkpoint inhibitors across several malignancies, notably non-small cell lung cancer. In addition, the firm pursues pre-clinical small-molecule immune therapies and holds an ownership position in SEED Therapeutics, which creates targeted protein degradation drugs in conjunction with prominent pharmaceutical collaborators.
The company maintains an international research footprint featuring corporate offices in New Jersey as well as facilities located in Beijing and Dalian, China, while its affiliate operates premises in Pennsylvania. Its clinical evaluations span numerous global testing centers across the United States, China, Australia, and several South American nations. BeyondSpring is legally organized and incorporated under the laws of the Cayman Islands.
Summary of the business section of BeyondSpring's latest annual report, written by StockData.
Company profile
Company
- Legal name
- BeyondSpring Inc.
- Headquarters
- Florham Park, NJ
- Address
- 100 Campus Drive, West Side, 4th Floor, Suite 410 07932
- Phone
- (646) 528-4184
- Website
- beyondspringpharma.com
- Employees
- 44, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Auditor
- CBIZ CPAs P.C., Costa Mesa, CA
Stock & identifiers
- Ticker
- BYSI
- Exchange
- Nasdaq
- IPO date
- Mar 9, 2017
- Shares outstanding
- 41M, Jul 31, 2026
- Public float
- $69.70M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1677940
- CUSIP
- G10830100
- ISIN
- USG108301007
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Lan Huang | Chief Executive Officer, Director | 476,760 |
| Na (NL) Li | Chief Financial Officer | – |
| Min Qiu | Chief Executive Officer | 2,498 |
| Yingjuan June Lu | Chief Scientific Officer | 100 |
| Jiangwen Majeti | Director | 50,914 |
| Matthew Kirkby | Director | – |
| Sihai Xu | Director | – |
| Brendan Delaney | Director | – |
| Patrick Fabbio | Director | 24,592 |
Employees
Headcount reported in annual reports
“As of February 27, 2026, we had 44 full-time employees, including 34 employed by SEED.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 6, 2026 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Oct 2, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Sep 18, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 11, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Feb 25, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Mar 9, 2017 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 6, 2017 | Listing | Registration of securities on an exchange (Form 8-A) |